NCT00517309View on ClinicalTrials.gov

Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,877

Participants

Timeline

Start Date

December 28, 2001

Primary Completion Date

June 8, 2004

Study Completion Date

June 11, 2004

Conditions
Cervical CancerGenital Warts
Interventions
BIOLOGICAL

V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years

BIOLOGICAL

Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00517309 - Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) | Biotech Hunter | Biotech Hunter